Paradromics' Connexus bet: first speech-restoring BCI implant lands in an FDA study

Paradromics builds the Connexus BCI: a brain implant with hundreds of microelectrodes that records neural signals and sends them through a chest transceiver to text or synthesized speech.

That a fully implantable, high-channel brain-computer interface could pass FDA scrutiny and beat less invasive rivals on communication speed for people who cannot speak.

$33 million Series A announced 2023-05-18, led by Prime Movers Lab (CNBC).

Matt Angle, a neuroscientist, founded Paradromics in Austin in 2015. Its Connexus platform records from hundreds of neurons; the company positioned it as an assistive communication device translating thought into text or synthesized speech.

The FDA granted Breakthrough Device designation in March 2023, and CNBC reported the company hoped to open its first human trial in the first half of 2024. A temporary Connexus implant in June 2025, during epilepsy research at U-M Health, confirmed the device could sit in the brain and record signals safely.

On 2026-06-16 neurosurgeons at University of Michigan Health implanted Connexus in the first participant of the FDA-approved Connect-One Early Feasibility Study, a Michigan woman with motor neuron disease who struggles to speak; she will be followed for six years.

The FDA process is the real product roadmap: each designation, exemption and study approval converts a research device into something hospitals can actually enroll patients around.

Paradromics picked an unmet need with measurable value: a person who cannot speak gains agency through communication, which is the emotional and clinical core of the pitch.

A fully implantable wireless design, with signal routed through the chest, is a differentiation bet that also simplifies daily use for a participant living with severe motor impairment.

Announcing milestones in step with regulators, not just engineers, is what kept coverage alive from the 2023 designation through the 2026 first-in-human implant.

In regulated deep tech, the milestone that unlocks value is the regulatory one: Breakthrough designation built an FDA relationship that carried a young company into first-in-human study.

As of 2026-06-17, Paradromics is running the Connect-One Early Feasibility Study at three US sites with one implanted participant and a six-year follow-up plan. The study is the first in a planned series of clinical applications for the Connexus platform, and Paradromics says it is building toward next-generation clinical BCIs rather than a single product launch.